Lantheus Holdings (LNTH) Stock

Lantheus Holdings (LNTH) is a successful company known for its strong products, PYLARIFY and DEFINITY, which are both growing rapidly and have a large market share. The management has performed exceptionally well, especially with PYLARIFY, which is expected to surpass $1 billion in sales by the end of 2024. The company is in a solid financial position, with almost $1 billion in cash, low debt, and strong cash flow, making it ready for potential acquisitions.

Carillon Tower Advisers, an investment management firm, published its third quarter 2024 investor letter for the "Carillon Eagle Small Cap Growth Fund." You can download the letter here. After facing losses in the second quarter, small-cap stocks saw a significant rise in the third quarter, with the Russell 2000 Growth Index increasing by 8.41%, although it still lagged behind the Russell 2000.

Lantheus Holdings' stock saw a significant increase on Wednesday. This rise can be attributed to positive news or developments related to the company. Investors reacted favorably, leading to a boost in the stock's value.

BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), a top company in radiopharmaceuticals dedicated to helping doctors detect, treat, and monitor diseases for improved patient care, has announced that its board of directors has approved a plan to buy back up to $250 million of its common stock over the next year.

Lantheus Holdings, Inc. (NASDAQ: LNTH), a top company in radiopharmaceuticals dedicated to helping doctors detect and treat diseases for improved patient care, has announced that Bob Marshall, the Chief Financial Officer and Treasurer, will speak at the Jefferies London Healthcare Conference. His presentation is scheduled for 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20.

Lantheus, which has a solid range of pharmaceutical products and has been growing rapidly, saw its stock drop by 20% after the third quarter of 2024 because of anticipated low earnings per share in the fourth quarter due to temporary costs. Their main products, Pylarify and Definity, improve diagnostic imaging for prostate cancer and heart issues, and they have a lot of market potential along with government backing. Even with a cautious outlook for the fourth quarter, Lantheus' forward price-to-earnings ratio of 13 and expected 15% annual revenue growth make it an appealing investment option.

Lantheus Holdings, Inc. (NASDAQ:LNTH) will hold its Q3 2024 Earnings Conference Call on November 5, 2024, at 8:00 AM ET. The call will feature company executives including Mark Kinarney, Brian Markison, and Bob Marshall, among others. Various participants from different financial firms will also join the call.

Lantheus Holdings, Inc. (NASDAQ: LNTH), a top company in radiopharmaceuticals, supports the Centers for Medicare & Medicaid Services' (CMS) final rule for the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). This rule, which was shared on the CMS website last Friday, highlights the importance of specialized diagnostic radiopharmaceuticals and aims to enhance patient access by adjusting payment amounts for these products.

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) has announced that it will hold a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024. The purpose of this event is to review its financial and operational results for the third quarter of 2024.